BR0314617A - Método para cardioproteção e neuroproteção por administração intravenosa de anestésico voláteis halogenados - Google Patents

Método para cardioproteção e neuroproteção por administração intravenosa de anestésico voláteis halogenados

Info

Publication number
BR0314617A
BR0314617A BR0314617-0A BR0314617A BR0314617A BR 0314617 A BR0314617 A BR 0314617A BR 0314617 A BR0314617 A BR 0314617A BR 0314617 A BR0314617 A BR 0314617A
Authority
BR
Brazil
Prior art keywords
cardioprotection
neuroprotection
intravenous administration
ischemic event
halogenated volatile
Prior art date
Application number
BR0314617-0A
Other languages
English (en)
Inventor
Raul Trillo
Ralph Lessor
Satish Pejaver
Navneet Puri
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of BR0314617A publication Critical patent/BR0314617A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Abstract

"METODO PARA CARDIOPROTEçãO E NEUROPROTEçãO POR ADMINISTRAçãO INTRAVENOSA DE ANESTéSICOS VOLáTEIS HALOGENADOS". A presente invenção refere-se a um método de tratamento de um paciente tendo um tecido que é submetido a um evento isquêmico. O método é conduzido por administração parenteral de uma formulação contendo um anestésico volátil halogenado, em uma quantidade eficaz para aperfeiçoar a resistência ou tolerância do tecido ao evento isquêmico. Na concretização preferida da invenção, a quantidade da formulação administrada ao paciente é subanestósica. A formulação pode ser administrada antes do, concorrentemente com ou após o evento isquêmico. O método pode ser usado, por exemplo, para tratamento de pacientes tendo tecido do miocárdio ou neuronal, que é submetido a um evento isquêmico.
BR0314617-0A 2002-10-11 2003-10-09 Método para cardioproteção e neuroproteção por administração intravenosa de anestésico voláteis halogenados BR0314617A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41793402P 2002-10-11 2002-10-11
PCT/US2003/031826 WO2004032858A2 (en) 2002-10-11 2003-10-09 Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics

Publications (1)

Publication Number Publication Date
BR0314617A true BR0314617A (pt) 2005-08-02

Family

ID=32094122

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314617-0A BR0314617A (pt) 2002-10-11 2003-10-09 Método para cardioproteção e neuroproteção por administração intravenosa de anestésico voláteis halogenados

Country Status (19)

Country Link
US (1) US7999011B2 (pt)
EP (1) EP1558226B1 (pt)
JP (1) JP5210486B2 (pt)
KR (2) KR101403264B1 (pt)
CN (2) CN1703209A (pt)
AT (1) ATE546136T1 (pt)
AU (1) AU2003282464B2 (pt)
BR (1) BR0314617A (pt)
CA (1) CA2500310C (pt)
DK (1) DK1558226T3 (pt)
ES (1) ES2382911T3 (pt)
HK (1) HK1079703A1 (pt)
IL (1) IL167472A (pt)
MX (1) MXPA05003741A (pt)
NZ (1) NZ539298A (pt)
PL (1) PL219493B1 (pt)
RU (1) RU2350323C2 (pt)
WO (1) WO2004032858A2 (pt)
ZA (1) ZA200502741B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
EP2081562B1 (en) * 2006-09-20 2016-02-24 The Board of Regents of The University of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
GB0619499D0 (en) 2006-10-03 2006-11-08 Lucent Technologies Inc Encrypted data in a wireless telecommunications system
DE112008002914A5 (de) * 2007-11-06 2010-09-30 B. Braun Melsungen Ag Einen hydrophoben Wirkstoff enthaltende wässrige Emulsionen
AU2015200210B2 (en) * 2008-01-22 2016-08-11 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
JP5789100B2 (ja) * 2008-01-22 2015-10-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抽出溶媒を含む、局部的な麻酔および／または疼痛低減のための揮発性麻酔薬組成物
CA2712516C (en) * 2008-01-22 2016-06-28 Vapogenix, Inc. Volatile anesthetic compositions and methods of use
WO2010129686A1 (en) * 2009-05-05 2010-11-11 Vapogenix, Inc. Novel formulations of volatile anesthetics and methods of use for reducing inflammation
EP2459182B1 (en) * 2009-07-30 2017-09-06 University of Zürich Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
FR2956323B1 (fr) * 2010-02-15 2013-12-20 Air Liquide Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques
CN103764128A (zh) * 2011-06-24 2014-04-30 维普詹尼克斯公司 用于治疗皮肤病症或疾病的新型制剂和方法
EP2968214B1 (en) 2013-03-15 2021-03-10 Vapogenix, Inc. Novel analgesic compositions
ITMO20130075A1 (it) 2013-03-22 2014-09-23 Enrico Giuliani Dispositivo di somministrazione

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1018773A (en) * 1962-09-13 1966-02-02 Bellon Labor Sa Roger ª‡-phenyl-ª‰-2-furyl-propionitrile derivatives
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US5628930A (en) 1992-10-27 1997-05-13 Alliance Pharmaceutical Corp. Stabilization of fluorocarbon emulsions
US5635538A (en) 1993-03-16 1997-06-03 Alliance Pharmaceutical Corp. Fluorocarbon emulsions with reduced pulmonary gas-trapping properties
JP2961034B2 (ja) * 1993-09-16 1999-10-12 アルプス電気株式会社 磁気ヘッド
EP0720605B1 (en) * 1993-09-24 2001-12-19 University Of British Columbia Aminocyclohexylesters and uses thereof
FR2726267B1 (fr) * 1994-10-26 1998-01-02 Smithkline Beecham Lab Nouveaux agents anti-arythmiques, compositions pharmaceutiques les contenant, et procede pour les preparer
GB2350297A (en) * 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
DE60132337T2 (de) 2000-07-26 2009-02-12 Taro Pharmaceutical Industries Ltd. Nicht-sedierende barbituratverbindungen als neuroprotektive wirkstoffe

Also Published As

Publication number Publication date
PL376217A1 (en) 2005-12-27
KR20120030598A (ko) 2012-03-28
CN1703209A (zh) 2005-11-30
EP1558226B1 (en) 2012-02-22
US7999011B2 (en) 2011-08-16
KR101403264B1 (ko) 2014-06-02
CN102283821A (zh) 2011-12-21
AU2003282464B2 (en) 2010-02-25
AU2003282464A1 (en) 2004-05-04
IL167472A (en) 2013-10-31
RU2350323C2 (ru) 2009-03-27
CA2500310C (en) 2013-03-12
ATE546136T1 (de) 2012-03-15
NZ539298A (en) 2008-11-28
EP1558226A2 (en) 2005-08-03
US20040127578A1 (en) 2004-07-01
JP5210486B2 (ja) 2013-06-12
HK1079703A1 (zh) 2006-04-13
WO2004032858A3 (en) 2004-09-23
EP1558226A4 (en) 2008-04-02
KR20050056230A (ko) 2005-06-14
PL219493B1 (pl) 2015-05-29
DK1558226T3 (da) 2012-05-07
RU2005114008A (ru) 2005-10-27
JP2006504740A (ja) 2006-02-09
ES2382911T3 (es) 2012-06-14
MXPA05003741A (es) 2005-06-17
ZA200502741B (en) 2006-02-22
CA2500310A1 (en) 2004-04-22
WO2004032858A2 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
HK1079703A1 (zh) 通過靜脈施用鹵化揮發性麻醉藥保護心臟和保護神經的方法
RUBIN Intracordal injection of silicone in selected dysphonias
Boezaart et al. Perineural infusion of local anesthetics
Compere et al. Major complications after 400 continuous popliteal sciatic nerve blocks for post‐operative analgesia
BRPI0406667A (pt) Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg
JP2006501240A5 (pt)
Podoshin et al. Effects of peritonsillar infiltration on post-tonsillectomy pain: a double-blind study
BR0315573A (pt) Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica
Younis et al. Taking the'ouch'out-effect of buffering commercial xylocaine on infiltration and procedure pain-a prospective, randomised, double-blind, controlled trial.
JP2001510795A5 (pt)
Jayakaran et al. Local anesthetics in pediatric dental practice
KR100535554B1 (ko) 소아과 수술에서의 레보부피바카인의 용도
Alioto et al. Hematoma block for ankle fractures: a safe and efficacious technique for manipulations
Kulkarni et al. Painless anaesthesia in pediatric dentistry: an updated review
BR0315609A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
Yaacob et al. The efficacy of xylocaine topical anaesthetic in reducing injection pain
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
Padmanabhan et al. Dental Anesthesia: Can Needle-Free Injections Help
Dalens Lower extremity nerve blocks in pediatric patients
Upadya et al. Anesthesia for dermatological surgery.
Gupta et al. Intrathecal administration of bupivacaine and bupivacaine with different doses of clonidine for post-operative analgesia in lower abdominal and lower limb surgeries–A comparative study
Arangannal et al. Intranasal Local Anaesthesia: A Recent Advancement in Pediatric Dentistry.
Srivastava et al. Clinical Evaluation Of Effects Of Acupuncture Anesthesia In Extraction Of Tooth.
Koh et al. Epinephrine-Induced Digital Vasospasm Reversed by a Phentolamine-Papaverine-Alprostadil Complex: A Case Report.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/02, A61K 9/107, A61K 47/24, A61K 47/44, A61K 31/02, A61P 25/00, A61P 25/08, A61P 9/10, A61P 43/00

Ipc: A61K 31/02 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 11, 13 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]